BRIUMVI is currently approved in the United States, as well as several countries outside of the U.S., as a one-hour intravenous (IV) infusion administered twice a year, following the starting dose, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback